Seattle, WA, United States of America

Siriphan Manocheewa

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Siriphan Manocheewa. Retrieved from https://idiyas.com/inventor/siriphan-manocheewa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Siriphan Manocheewa: Innovator in Immunology

Introduction

Siriphan Manocheewa is an inventor based in Seattle, WA (US). He has made significant contributions to the field of immunology, particularly in the development of methods to induce immune responses against HIV. Although he currently holds no granted patents, his work is noteworthy for its potential impact on public health.

Latest Patent Applications

Siriphan Manocheewa's latest patent applications include "Methods and Compositions for Inducing an Immune Response Using Conserved Element Constructs." This invention provides methods and compositions for eliciting broad immune responses to HIV envelope proteins. The methods include the use of nucleic acid constructs that encode conserved elements of HIV Env to induce immune responses.

Conclusion

Siriphan Manocheewa's innovative approaches in immunology highlight the importance of research in combating diseases like HIV. His contributions, although not yet patented, pave the way for future advancements in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…